financetom
Business
financetom
/
Business
/
Ciena Fiscal Second-Quarter Earnings Miss Street Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ciena Fiscal Second-Quarter Earnings Miss Street Views
Jun 5, 2025 6:27 AM

09:00 AM EDT, 06/05/2025 (MT Newswires) -- Ciena (CIEN) reported higher fiscal second-quarter results year over year on Thursday, but the networking systems and software company's earnings fell short of Wall Street's estimates.

The company's adjusted earnings came in at $0.42 per share for the quarter ended May 3, up from $0.27 a year earlier. However, the result missed the consensus on FactSet for a larger increase to $0.52. Shares of the firm were down 2.4% in premarket activity.

Revenue climbed 24% year over year to $1.13 billion, topping the Street's view for $1.09 billion.

"With accelerating demand driven by cloud and (artificial intelligence), our performance is validating the durability of a positive network infrastructure spending environment," Chief Executive Gary Smith said in a statement. "As a result, we have strong visibility and are very confident in both our continued growth and our ability to drive additional operating leverage over time."

Sales for the networking platform segment amounted to $866.3 million, up from $676.3 million in the prior-year period. Within the division, optical networking advanced to $773.6 million from $560.2 million, while routing and switching dropped to $92.7 million from $116.1 million. The global services business saw revenue incline to $146.2 million from $134.7 million a year ago.

By geography, revenue in the Americas, which represented about 74% of Ciena's total sales during the quarter, grew to $833.8 million from $662.9 million. Asia-Pacific and Europe, the Middle East and Africa also logged gains.

The company's gross margin fell to 40.2% from 42.7% in the 2024 quarter. Total operating expenses rose to nearly $420 million from $392.6 million on an annual basis, according to the company.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Patron Capital among bidders for Legal & General housebuilder CALA-source
Patron Capital among bidders for Legal & General housebuilder CALA-source
Jun 12, 2024
LONDON, June 12 (Reuters) - Patron Capital Partners is one of the bidders for Legal & General's ( LGGNF ) housebuilder CALA, in a deal expected to raise around one billion pounds ($1.28 billion), a source familiar with the matter said on Wednesday. Legal & General ( LGGNF ) announced a revamp of its business on Wednesday, saying that CALA...
Jim Cramer: 'GameStop Won,' Bears Are Going To Retreat As Ryan Cohen Turns Stock Into Pseudo-SPAC, Embarks On 'Chewy 2'
Jim Cramer: 'GameStop Won,' Bears Are Going To Retreat As Ryan Cohen Turns Stock Into Pseudo-SPAC, Embarks On 'Chewy 2'
Jun 12, 2024
Jim Cramer has declared victory for GameStop Corp ( GME ) after the video game retailer announced the completion of its at-the-market equity offering. Cramer believes a transformation could be on the horizon. What To Know: GameStop ( GME ) shares got a lift late Tuesday after the company said it sold the maximum number of shares registered under its...
--Sony Reportedly Buys Alamo Drafthouse Movie Theatre Chain
--Sony Reportedly Buys Alamo Drafthouse Movie Theatre Chain
Jun 12, 2024
02:20 PM EDT, 06/12/2024 (MT Newswires) -- Price: 84.36, Change: -0.64, Percent Change: -0.75 ...
Palatin Technologies Starts Phase 2 of Obesity Treatment Study
Palatin Technologies Starts Phase 2 of Obesity Treatment Study
Jun 12, 2024
02:16 PM EDT, 06/12/2024 (MT Newswires) -- Palatin Technologies ( PTN ) said Wednesday it has started a phase 2 clinical trial to assess the safety and efficacy of bremelanotide, a melanocortin 4 receptor agonist, administered alongside tirzepatide, for treating obesity. Topline data from the study, which will involve up to 60 patients who are actively on tirzepatide across five...
Copyright 2023-2026 - www.financetom.com All Rights Reserved